Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2026-02-03 @ 3:48 AM
Study NCT ID:
NCT05108766
Status:
COMPLETED
Last Update Posted:
2023-04-12
First Post:
2021-10-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
Sponsor:
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Plaque Psoriasis | View |
Keywords: